# Buntanetap/posiphen PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/buntanetap-posiphen

> The next catalyst for buntanetap/posiphen, sponsored by Annovis Bio, Inc. (ANVS), is its primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | buntanetap/posiphen |
| Codes |  |
| Sponsor | Annovis Bio, Inc. (ANVS) https://sec-api.dev/companies/anvs/catalysts |
| Indications | [Early Alzheimers Disease](https://sec-api.dev/indications/early-alzheimers-disease), [Alzheimer's Dementia (AD)](https://sec-api.dev/indications/alzheimer-s-dementia-ad), [Parkinson's Disease (PD)](https://sec-api.dev/indications/parkinson-s-disease-pd) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Early Alzheimers Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06709014 (A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." https://clinicaltrials.gov/study/NCT06709014

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Early Alzheimers Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06709014 (A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." https://clinicaltrials.gov/study/NCT06709014

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Parkinson's Disease (PD); Deep Brain Stimulation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07284784 (A Study of Buntanetap in Participants With PD): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." https://clinicaltrials.gov/study/NCT07284784

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Parkinson's Disease (PD); Deep Brain Stimulation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07284784 (A Study of Buntanetap in Participants With PD): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." https://clinicaltrials.gov/study/NCT07284784

### Feb to May 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Alzheimer's Dementia (AD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07757204 (An Open-label Long-term Safety Study of Buntanetap in Participants With AD): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-02-21 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." https://clinicaltrials.gov/study/NCT07757204

### February 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Alzheimer's Dementia (AD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07757204 (An Open-label Long-term Safety Study of Buntanetap in Participants With AD): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-02-21 (ESTIMATED); Lead Sponsor Annovis Bio Inc.." https://clinicaltrials.gov/study/NCT07757204

## Same indication

- [Foscarbidopa](https://sec-api.dev/pdufa/foscarbidopa) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/buntanetap-posiphen.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Buntanetap/posiphen PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/buntanetap-posiphen

```bibtex
@misc{secapidev_pdufa_buntanetap_posiphen_20261116,
  title        = {Buntanetap/posiphen PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/buntanetap-posiphen}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_buntanetap_posiphen_20261116","title":"Buntanetap/posiphen PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/buntanetap-posiphen","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
